Inactive Instrument

Cubist Pharmaceuticals Inc Stock

Stocks

End-of-day quote Nasdaq
- ^USD	-

14-12-09	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
14-12-09	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE

14-12-09	Cubist Pharmaceuticals : sales force seen as potential boon for Merck intestinal drug	RE
14-12-09	Cubist Pharmaceuticals : Merck says still plans to buy Cubist, despite patent setback	RE
14-12-09	Merck : to take on superbugs with Cubist Pharma buy	RE
14-12-08	AstraZeneca : Merck to take on superbugs with Cubist Pharma buy	RE
14-12-08	Apple : S&P 500 posts worst day since Oct; energy shares sink	RE
14-12-08	Cubist Pharmaceuticals : options unusually active before Merck deal	RE
14-12-05	Cubist Pharmaceuticals : Merck in talks to acquire Cubist Pharmaceuticals for more than $7 billion - NYT	RE
13-05-20	Cubist Pharmaceuticals Inc : U.S. court ruling favors Cubist in patent case versus Hospira	RE

15-01-13	Cubist Pharmaceuticals : Announces Withdrawal of Listing of CVRs (CBSTZ) from NASDAQ Global Select Market	BU
14-12-19	Cubist Pharmaceuticals : Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections	BU
14-12-15	Cubist Pharmaceuticals : SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company	PR
14-12-12	Cubist Pharmaceuticals : SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Cubist Pharmaceuticals, Inc. And Encourages Investors To Contact The Firm For Additional Information	BU
14-12-12	Cubist Pharmaceuticals : CBST SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. in Connection With the Fairness of the Sale of the Company to Merck & Co.	BU

14-12-21	Cubist Pharmaceuticals : meldet FDA-Zulassung seines neuen Antibiotikums ZERBAXA™ (Ceftolozan/Tazobactam) für komplizierte Harnwegsinfektionen und komplizierte intraabdominelle Infektionen
14-12-20	Cubist Pharmaceuticals : annonce l’approbation par la FDA du nouvel antibiotique ZERBAXA™ (ceftolozane/tazobactam) pour le traitement des infections urinaires compliquées et des infections intra-abdominales compliquées
14-12-09	Merck : compte toujours acheter Cubist malgré un souci sur le Cubicin
14-12-08	Cubist Pharmaceuticals : Merck & Co acquiert Cubist Pharma pour 8,4 milliards de dollars
14-12-08	Cubist Pharmaceuticals : Wall Street ouvre en baisse, l'Asie inquiète

Manager	Title	Age	Since
Karen Rogers PRN	Corporate Officer/Principal	-	-
Phyllis Rae Abbuhl SAM	Sales & Marketing	-	-
Frederick B. Oleson PRN	Corporate Officer/Principal	-	1996-12-31

Director	Title	Age	Since
Martin Hermanus Soeters BRD	Director/Board Member	72	2006-08-31
Kenneth J. Martin BRD	Director/Board Member	72	2013-09-24

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
REGENERON PHARMACEUTICALS, INC.	-0.31%	+2.44%	+38.43%	+0.77%	80.23B
SAMSUNG BIOLOGICS CO.,LTD.	-1.02%	-0.51%	-2.54%	+28.91%	50.64B
UCB	-3.10%	-4.84%	+10.29%	+160.49%	46.87B
CSL LIMITED	+0.29%	+1.64%	-49.63%	-49.30%	46.34B
BIOGEN INC.	-0.39%	+0.91%	+51.39%	-20.90%	31B
MODERNA, INC.	-0.52%	+7.01%	+125.98%	-35.99%	25.28B
INCYTE CORPORATION	-0.30%	-0.33%	+38.24%	+85.63%	24.36B
INNOVENT BIOLOGICS, INC.	+2.67%	-0.87%	-5.35%	+194.95%	20.81B
SWEDISH ORPHAN BIOVITRUM AB	-1.83%	-2.82%	+60.85%	+109.32%	16.08B
Average	-0.50%	+1.44%	+29.74%	+52.65%	37.96B
Weighted average by Cap.	-0.64%	+1.13%	+22.58%	+38.36%

Employees

Sector